Gilead Sciences, Inc.
NEWS
The United Kingdom’s government-funded health service isn’t being so nice to Gilead Science’s CAR-T blood cancer treatment Yescarta. The country’s National Institute for Health and Care Excellence (NICE) said the therapy is too expensive for the agency to justify.
Novartis announced that its BYL719 (alpelisib) met the primary endpoint of progression-free survival (PFS) in its Phase III SOLAR-1 trial. The drug is an alpha-specific PI3K inhibitor, a category of cancer drugs that has a troubling history of adverse events.
By many standards, and certainly by the way the media covers it and industry promotes it, immuno-oncology therapies using CAR-T are revolutionizing cancer treatments. But what if, as the saying goes, they threw a revolution and nobody came? Or more precisely, what if they threw a revolution and no one was willing to pay for it?
Vancouver, British Columbia-based Sierra Oncology acquired momelotinib from Gilead Sciences in a deal that could hit $198 million.
This past week’s roundup of Movers and Shakers in the biotech industry started with a surprise. Gilead Science’s new(ish) chief medical officer was leaving the company six months after taking over the position.
Foster City, Calif.-based Gilead Sciences reorganized some of its executive leadership team after it was announced that Chief Medical Officer Andrew Cheng is leaving the company to pursue other opportunities.
Janssen Pharmaceutical Companies from Johnson & Johnson, confirmed topline data from its Phase III Antiretroviral Therapy as Long-Acting Suppression (ATLAS) trial of its two-drug combination for HIV.
It’s not easy to predict trends in drugs, especially with breakthroughs in immunology and genetic engineering often causing dramatic changes in how biopharma companies approach new drugs.
Gilead Sciences’ president and chief executive officer, John Milligan, is retiring after 28 years with the company. Gilead is beginning a search for a replacement.
JOBS
IN THE PRESS